Rigel Pharmaceuticals | RIGL - Trade Debtors


Rigel Pharmaceuticals reported $28.9M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agenus USD 22.44M 1.14M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
AstraZeneca USD 17.88B 1.17B Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Celldex Therapeutics USD 2.02M 1.92M Dec/2025
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
MacroGenics USD 13.37M 55.86M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Pfizer USD 15.84B 2.27B Dec/2025
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Ultragenyx Pharmaceutical USD 158M 45.46M Dec/2025
Veracyte USD 44.66M 3.17M Dec/2025